Drug Trial Radar · NCT03710434
AZD4635 Relative Bioavailability Study
Last checked: Nov 19, 2026Latest source record: May 7, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
21
Actual
Start
Nov 1, 2018
Primary completion
Apr 2, 2019
Study completion Apr 2, 2019
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Quotient Sciences
- First posted
- Oct 18, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To investigate the pharmacokinetics and relative bioavailability of AZD4635 solid oral formulation and compare with the nano-suspension reference formulation with the option to assess food effect, pH effect and absolute bioavailability
Conditions
- Healthy Volunteers
Interventions
AZD4635 50 mg nano-suspension (reference)Drug
Subjects will receive a single dose of AZD4635 50 mg nano-suspension (reference) in the fasted state.
AZD4635 solid oral formulation - fastedDrug
Subjects will receive a single dose of AZD4635 solid oral formulation, in the fasted state.
AZD4635 solid oral formulation - fedDrug
Subjects will receive a single dose of AZD4635 solid oral formulation, in the fed state.
Lansoprazole and AZD4635 50 mg solid oral formulationDrug
Subjects will receive lansoprazole 30 mg BID for 5 days followed by a single dose of AZD4635 50 mg solid oral formulation in the fasted state.
AZD4635 solid oral formulation variant 1 - fastedDrug
Subjects will receive a single dose of AZD4635 solid oral formulation, variant 1 in the fasted state.
AZD4635 solid oral formulation variant 2 - fastedDrug
Subjects will receive a single dose of AZD4635 solid oral formulation, variant 2 in the fasted state.
[14C] AZD4635 IV microtracer - fastedDrug
Subjects will receive a single dose of \[14C\] AZD4635 IV microtracer. This intervention will be co-administered with AZD4635 solid oral formulation variant 1.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum observed plasma concentration (Cmax) of AZD4635 solid oral formulation and nano-suspension (reference)Time frame: Blood samples collected pre-dose, and postdose at 0.25h, 0.5h, 1h, 1.5h, 2h, 4h, 6h, 8h, 12h, 24h, 48h, 72h, 96h and 120h
- Exposure to AZD4635 solid oral formulation and nano-suspension (reference)Time frame: Blood samples collected pre-dose, and postdose at 0.25h, 0.5h, 1h, 1.5h, 2h, 4h, 6h, 8h, 12h, 24h, 48h, 72h, 96h and 120h
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Research Site
Ruddington, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.